Oral Factor D Inhibitor Fails to Improve Myasthenia Gravis Symptoms

The Evolving Landscape of Complement Inhibition in Myasthenia Gravis

Generalized myasthenia gravis remains a complex autoimmune challenge characterized by fluctuating skeletal muscle weakness and the potential for life-threatening respiratory failure [1]. While traditional management relies on corticosteroids and broad immunosuppressants, therapeutic focus has recently shifted toward targeting the complement cascade, which drives postsynaptic membrane damage at the neuromuscular junction [2, 3]. Currently approved terminal complement inhibitors have demonstrated efficacy in refractory cases, yet these agents require intravenous or subcutaneous administration and carry a well-documented risk of meningococcal infection [4, 5]. Researchers have hypothesized that inhibiting the alternative complement pathway might preserve baseline immune function while offering the convenience of oral dosing [6, 7]. A recent multicenter trial investigated whether this strategy could provide a viable, safer alternative to existing biologics for daily clinical practice.

Targeting the Alternative Pathway with Oral Vemircopan

Current therapeutic strategies for acetylcholine receptor antibody-positive generalized myasthenia gravis often involve the inhibition of terminal complement component 5. While this mechanism effectively manages the disease by halting the final stages of the inflammatory cascade, it presents significant clinical hurdles, including the requirement for intravenous or daily subcutaneous administration. Furthermore, clinicians must manage a well-documented increased risk of meningococcal infection associated with terminal complement blockade. To address these limitations, the researchers evaluated vemircopan, an oral, selective factor D inhibitor. Factor D is an enzyme crucial for activating the alternative pathway of the complement system. By blocking this specific amplification loop, vemircopan was designed to halt disease-driving inflammation while preserving the classical and lectin pathways, which are essential for maintaining baseline immune responses against bacterial infections. For practicing physicians, this selective inhibition theoretically offered a way to mitigate the heightened vulnerability to pathogens like Neisseria meningitidis while reducing the logistical burden of infusions.

Trial Design and Patient Characteristics

The researchers conducted a double-blind, parallel-group, placebo-controlled phase 2 randomized clinical trial between April 14, 2022, and April 3, 2024. To ensure broad clinical representation, the investigators recruited participants from 60 sites across 8 countries. Eligible participants were adults diagnosed with acetylcholine receptor antibody-positive generalized myasthenia gravis. Clinical severity at enrollment was defined by a Myasthenia Gravis-Activities of Daily Living (MG-ADL) score of 5 or greater, a standard patient-reported scale assessing the impact of symptoms on daily functions like speech, swallowing, and respiratory effort. Additionally, patients were required to meet the criteria for Myasthenia Gravis Foundation of America classes II through IV, a classification system indicating mild to severe muscle weakness without intubation. Of the 99 individuals screened, 70 met the eligibility criteria and were randomized into the treatment arms. The study utilized a 2:1:2 randomization protocol, assigning participants to receive either twice-daily oral vemircopan at a dose of 180 mg (n = 28), vemircopan at 120 mg (n = 14), or a placebo (n = 28). Within this cohort, 38 participants (54%) were female, and the mean (SD) age at diagnosis was 45.4 (18.5) years.

Primary and Secondary Efficacy Outcomes

The primary efficacy end point was defined as the proportion of participants achieving a reduction of 2 points or greater in the Myasthenia Gravis-Activities of Daily Living total score from baseline. To meet this clinical threshold, the improvement had to be sustained for 4 consecutive weeks without the use of rescue therapy during the 8-week primary evaluation period. Following the unblinding of data in June 2024, the results indicated that the oral factor D inhibitor did not provide a clinical advantage over the control group. Surprisingly, 18 of 28 participants (64%; 90% CI, 47% to 79%) in the placebo group achieved the primary end point. In comparison, only 16 of 28 participants (57%; 90% CI, 40% to 73%) in the 180 mg vemircopan group and 8 of 14 participants (57%; 90% CI, 33% to 79%) in the 120 mg vemircopan group met these criteria. Statistical analysis confirmed that no significant differences were observed between the placebo group and either vemircopan dosage group regarding the primary outcome. This lack of efficacy extended to the secondary end points, which measured various dimensions of disease burden and physical function. These secondary measures included the change from baseline to week 8 in the Myasthenia Gravis-Activities of Daily Living total score, the Quantitative Myasthenia Gravis total score (a physician-administered assessment of objective muscle strength and endurance), and the Neurological Disorders Fatigue questionnaire score. The researchers reported that no significant differences were observed for any of these secondary end points, confirming that the drug failed to alter the clinical trajectory of the disease.

Safety Profile and Study Termination

The safety profile of vemircopan was a critical focus of the trial, particularly regarding the risk of encapsulated bacterial infections. Because terminal complement inhibitors typically require strict vaccination protocols due to an increased risk of Neisseria meningitidis, it was notable that no cases of meningococcal infection were reported among the 70 randomized participants. This observation aligns with the hypothesis that selective factor D inhibition preserves the classical and lectin pathways necessary for defending against certain pathogens. However, other serious adverse events did occur during the evaluation period. Specifically, one participant died due to hepatic failure, and one participant discontinued study treatment due to herpes simplex meningitis, a severe viral infection of the central nervous system. Ultimately, the lack of clinical separation from the placebo group led to the cessation of the clinical program for this indication. The researchers concluded that vemircopan did not meet the prespecified threshold for efficacy, as it failed to demonstrate a significant reduction in symptom burden compared to the control group. Because the primary and secondary end points were not achieved, the study was terminated following the final analysis in October 2024. For practicing physicians, these results provide a clear clinical takeaway: while oral alternative pathway inhibition offered a theoretically safer and more convenient pharmacological strategy, it failed to deliver the robust clinical improvement currently achieved with established terminal complement therapies in patients with generalized myasthenia gravis.

References

1. Gerischer L, Doksani P, Hoffmann S, Meisel A. New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making. BioDrugs. 2025. doi:10.1007/s40259-024-00701-1

2. Cavalcante P, Mantegazza R, Antozzi C. Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis. Frontiers in Immunology. 2024. doi:10.3389/fimmu.2024.1404191

3. Rossini E, Leonardi L, Morino S, Antonini G, Fionda L. Immunological Targets in Generalized Myasthenia Gravis Treatment: Where Are We Going Now?. Brain Sciences. 2025. doi:10.3390/brainsci15090978

4. Salazar A, Mokhtari S, Peguero E, Jaffer M. The Role of Complement in the Pathogenesis and Treatment of Myasthenia Gravis. Cells. 2025. doi:10.3390/cells14100739

5. Wang Y, Nao J, Duan Y, Li Z, Feng J. Therapeutic strategies targeting complement in myasthenia gravis patients. Journal of Neurology. 2025. doi:10.1007/s00415-025-13225-7

6. Michailidou I, Patsiarika A, Kesidou E, et al. The role of complement in the immunopathogenesis of acetylcholine receptor antibody-positive generalized myasthenia gravis: bystander or key player?. Frontiers in Immunology. 2025. doi:10.3389/fimmu.2025.1526317

7. Tamdin T, Rodgers GM. Advances in Complement Inhibition Therapies for Paroxysmal Nocturnal Hemoglobinuria and Autoimmune Hemolytic Disorders. Journal of Blood Medicine. 2025. doi:10.2147/jbm.s543272